![]() |
|
![]() |
|
Systematic (IUPAC) name | |
---|---|
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
|
|
Clinical data | |
Trade names | Brovana |
AHFS/Drugs.com | monograph |
MedlinePlus | a602023 |
License data |
|
Pregnancy category |
|
Routes of administration |
Inhalation solution for nebuliser |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 52–65% |
Biological half-life | 26 hours |
Identifiers | |
CAS Number | 67346-49-0 ![]() |
ATC code | none |
PubChem | CID 3083544 |
IUPHAR/BPS | 7479 |
DrugBank | DB01274 ![]() |
ChemSpider | 2340731 ![]() |
UNII | F91H02EBWT ![]() |
ChEBI | CHEBI:408174 ![]() |
ChEMBL | CHEMBL1201137 ![]() |
Chemical data | |
Formula | C19H24N2O4 |
Molar mass | 344.405 g/mol |
|
|
![]() ![]() |
Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]
It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.
References
- ^ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.
External links
- Brovana website
|